Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
⏸️ Investing
8 shares you need to watch on Wednesday
⏸️ Investing
9 shares you should have been watching on Tuesday
⏸️ Investing
Why these 4 ASX shares have sunk lower today
⏸️ Investing
Mayne Pharma Group Ltd shares sink on trading update
⏸️ Investing
Should you buy these beaten down ASX shares?
⏸️ Investing
7 shares you need to watch on Tuesday
⏸️ Investing
ALL ORDINARIES finishes higher Monday: 6 shares you missed
⏸️ Investing
Can Mayne Pharma Group Ltd turn itself around?
⏸️ Investing
9 shares you should have been watching on Friday
⏸️ Investing
Why these 4 ASX shares are ending the week in the red
⏸️ Investing
Mayne Pharma Group Ltd share price falls another 7.6%
⏸️ Investing
3 ASX shares at 52-week lows: Is it time to buy?
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
